The company's portfolio consists of 9 first-in-class and bioBetters medicines based on three technological platforms, including PolyXEN, Histone, and Gemacell. With 8 products in phase 2 trials, SynBio's pipeline targets liver disease, cardiovascular disease, acute leukemia, growth hormone deficiency, and diabetes mellitus. Since its inception in 2011, SynBio has been a collaborative effort between Russian and international pharmaceutical companies, aiming to create groundbreaking treatments for devastating diseases.